New Study Reveals Higher Rates of Health Problems Among Cannabis Users with Psychotic Disorders
A recent study conducted by the University of Washington has found that cannabis users with psychotic disorders, such as schizophrenia, are more likely to experience a range of physical and mental health problems compared to those without mental health diagnoses. The study, which analyzed survey responses from over 4,000 cannabis users in Washington state, revealed that users with psychotic disorders reported higher rates of nausea, dizziness, and heart problems, which they attributed to their cannabis use.
Researchers found that almost 18% of cannabis users with psychotic disorders reported experiencing hallucinations or psychotic episodes over the past year, compared to just 3% of those without a mental health diagnosis. Additionally, nearly 21% of participants with psychotic disorders reported experiencing nausea and vomiting related to their cannabis use, while only 5% of those without a mental health diagnosis reported the same symptoms.
The study’s lead researcher, Beatriz Carlini, noted that the findings highlight the importance of considering the potential health risks associated with cannabis use, particularly for individuals with pre-existing mental health conditions. Carlini emphasized that while cannabis can have benefits, it is essential to recognize the potential drawbacks and take steps to mitigate them.
The study’s results also underscore the need for more comprehensive data collection and research on the effects of cannabis use on mental and physical health. Carlini suggested that future studies should aim to diversify their data sources, including medical records and physician documentation, to gain a more accurate understanding of the complex relationships between cannabis use and overall health.
In the meantime, the researchers have developed an online guide to help behavioral health clinicians discuss the potential effects of cannabis use with their patients and are recommending that warning labels be placed on cannabis products marketed towards users with mental health diagnoses like psychotic disorders.
